Fenofibrate
| Clinical data | |
|---|---|
| Trade names | Tricor, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601052 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 99% |
| Metabolism | glucuronidation |
| Elimination half-life | 20 h |
| Excretion | urine (60%), feces (25%) |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.051.234 |
| Chemical and physical data | |
| Formula | C20H21ClO4 |
| Molar mass | 360.83 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 80 to 81 °C (176 to 178 °F) |
SMILES
| |
InChI
| |
| (verify) | |
Fenofibrate, sold under the brand name Tricor among others, is an oral medication of the fibrate class used to treat abnormal blood lipid levels.[4] It is less commonly used compared to statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.[4][5][6] Its use is recommended together with dietary changes.[4]
Common side effects include liver problems, breathing problems, abdominal pain, muscle problems, and nausea.[4] Serious side effects may include toxic epidermal necrolysis, rhabdomyolysis, gallstones, and pancreatitis.[4] Use during pregnancy and breastfeeding is not recommended.[7][8] It works by multiple mechanisms.[4]
It was patented in 1969, and came into medical use in 1975.[9] It is available as a generic medication.[7] In 2022, it was the 88th most commonly prescribed medication in the United States, with more than 7 million prescriptions.[10][11]
- ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
- ^ "Fenofibrate 267mg Capsules - Summary of Product Characteristics (SmPC)". (emc). 12 February 2020. Retrieved 13 April 2020.
- ^ "Tricor- fenofibrate tablet". DailyMed. 14 November 2024. Retrieved 2 May 2025.
- ^ a b c d e f "Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. (April 2010). "Effects of combination lipid therapy in type 2 diabetes mellitus". The New England Journal of Medicine. 362 (17): 1563–1574. doi:10.1056/NEJMoa1001282. PMC 2879499. PMID 20228404.
- ^ Kim NH, Han KH, Choi J, Lee J, Kim SG (September 2019). "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study". BMJ. 366: l5125. doi:10.1136/bmj.l5125. PMC 6763755. PMID 31562117. S2CID 203580658.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 198. ISBN 9780857113382.
- ^ "Fenofibrate Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 474. ISBN 9783527607495.
- ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- ^ "Fenofibrate Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.